Sponging off nature for new drug leads

Biochem Pharmacol. 2017 Sep 1:139:3-14. doi: 10.1016/j.bcp.2017.04.012. Epub 2017 Apr 12.

Abstract

Marine sponges have consistently been the richest source of new marine natural products with unprecedented chemical scaffolds and potent biological activities that have been reported in the chemical literature since the early 1970s. During the last 40years, chemists in the Andersen laboratory at UBC, in collaboration with biologists, have discovered many novel bioactive sponge natural products. Four experimental drug candidates for treatment of inflammation and cancer, that were inspired by members of this sponge natural product collection, have progressed to phase I/II/III clinical trials. This review recounts the scientific stories behind the discovery and development of these four drug candidates; IPL576,092, HTI-286 (Taltobulin), EPI-506 (Ralaniten acetate), and AQX-1125.

Keywords: Drug discovery; Marine natural products; Porifera.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Asthmatic Agents / adverse effects
  • Anti-Asthmatic Agents / chemistry
  • Anti-Asthmatic Agents / pharmacology
  • Anti-Asthmatic Agents / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / chemistry
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antimitotic Agents / adverse effects
  • Antimitotic Agents / chemistry
  • Antimitotic Agents / pharmacology
  • Antimitotic Agents / therapeutic use
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Aquatic Organisms / chemistry*
  • Benzhydryl Compounds / adverse effects
  • Benzhydryl Compounds / chemistry
  • Benzhydryl Compounds / pharmacology
  • Benzhydryl Compounds / therapeutic use
  • Biological Products / chemistry*
  • Biological Products / isolation & purification
  • Cyclohexanols / adverse effects
  • Cyclohexanols / chemistry
  • Cyclohexanols / therapeutic use
  • Drug Design*
  • Drug Discovery*
  • Drugs, Investigational / adverse effects
  • Drugs, Investigational / chemistry*
  • Drugs, Investigational / pharmacology
  • Drugs, Investigational / therapeutic use
  • Glycerol / analogs & derivatives
  • Glycerol / pharmacology
  • Glycerol / therapeutic use
  • Humans
  • Indans / adverse effects
  • Indans / chemistry
  • Indans / therapeutic use
  • Nonsteroidal Anti-Androgens / adverse effects
  • Nonsteroidal Anti-Androgens / chemistry
  • Nonsteroidal Anti-Androgens / pharmacology
  • Nonsteroidal Anti-Androgens / therapeutic use
  • Oligopeptides / adverse effects
  • Oligopeptides / chemistry
  • Oligopeptides / pharmacology
  • Oligopeptides / therapeutic use
  • Porifera / chemistry*
  • Prodrugs / adverse effects
  • Prodrugs / chemistry
  • Prodrugs / pharmacology
  • Prodrugs / therapeutic use
  • Pyrrolidinones / adverse effects
  • Pyrrolidinones / chemistry
  • Pyrrolidinones / isolation & purification
  • Pyrrolidinones / therapeutic use
  • Sterols / adverse effects
  • Sterols / chemistry
  • Sterols / pharmacology
  • Sterols / therapeutic use

Substances

  • 4-(4-(aminomethyl)-7a-methyl-1-methylideneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexan-1-ol
  • Anti-Asthmatic Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antimitotic Agents
  • Antineoplastic Agents
  • Benzhydryl Compounds
  • Biological Products
  • Cyclohexanols
  • Drugs, Investigational
  • HTI-286
  • IPL576,092
  • Indans
  • Nonsteroidal Anti-Androgens
  • Oligopeptides
  • Prodrugs
  • Pyrrolidinones
  • Sterols
  • Glycerol

Grants and funding